1 – 50 of 2172
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis
2024) In Leukemia(
- Contribution to journal › Letter
-
Mark
Recombinant factor IX Fc for the treatment of hemophilia B
2024) In European Journal of Haematology(
- Contribution to journal › Scientific review
-
Mark
Haemophilia A - In pursuit of optimised outcomes via personalised treatment
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
2024) In The Lancet Haematology(
- Contribution to journal › Article
-
Mark
Large differencies in age-specific survival in multiple myeloma in the nordic countries
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression
2024) In Leukemia(
- Contribution to journal › Letter
-
Mark
Red blood cell-derived arginase release in hemolytic uremic syndrome
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
A machine-learning method for biobank-scale genetic prediction of blood group antigens
(
- Contribution to journal › Article
-
Mark
A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia
2024) In Leukemia(
- Contribution to journal › Article
-
Mark
Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy
2024) In European Journal of Haematology(
- Contribution to journal › Article
-
Mark
Population scale proteomics enables adaptive digital twin modelling in sepsis
2024)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Empowering macrophages : the cancer fighters within the tumour microenvironment in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Evidence that CD36 is expressed on red blood cells and constitutes a novel blood group system of clinical importance
(
- Contribution to journal › Article
-
Mark
Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Elucidating the Blood Group Regulome
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Prophylactic Treatment of Children with Hemophilia in Sweden
2024) In Seminars in Thrombosis and Hemostasis(
- Contribution to journal › Scientific review
- 2023
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
-
Mark
A novel GYP(B-A-B) hybrid in a blood donor identified by a phenotyping discrepancy with different anti-s reagents
(
- Contribution to journal › Article
-
Mark
A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes
(
- Contribution to journal › Article
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
-
Mark
Intracranial Hemorrhages in Neonates : Incidence, Risk Factors and Treatment
(
- Contribution to journal › Article
-
Mark
A large cohort study of the effects of Lewis, ABO, 13 other blood groups, and secretor status on COVID-19 susceptibility, severity, and long COVID-19
(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
-
Mark
Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII
(
- Contribution to journal › Article
-
Mark
Dilemmas on emicizumab in children with haemophilia A : A survey of strategies from PedNet centres
(
- Contribution to journal › Article
-
Mark
The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia
(
- Contribution to journal › Scientific review
-
Mark
Use of a recombinant deacetylase to convert A1 red blood cells to the acquired B phenotype for quality control purposes
2023) In Blood Transfusion(
- Contribution to journal › Article
-
Mark
Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy
(
- Contribution to journal › Scientific review
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Functional and molecular profiling of hematopoietic stem cells during regeneration
(
- Contribution to journal › Article
-
Mark
Genetic prediction of 33 blood group phenotypes using an existing genotype dataset
(
- Contribution to journal › Article
-
Mark
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
2023) In Leukemia(
- Contribution to journal › Article
-
Mark
Desialylated Platelet Clearance in the Liver is a Novel Mechanism of Systemic Immunosuppression
(
- Contribution to journal › Article
-
Mark
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
(
- Contribution to journal › Article
-
Mark
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
(
- Contribution to journal › Article
-
Mark
Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A : data from the PedNet Hemophilia Cohort of 1,202 children
2023) In Haematologica(
- Contribution to journal › Article
-
Mark
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma : The Swedish MCL complete Project
(
- Contribution to journal › Article
-
Mark
Engineered human Diamond-Blackfan anemia disease model confirms therapeutic effects of clinically applicable lentiviral vector at single-cell resolution
(
- Contribution to journal › Article
-
Mark
Skin mesenchymal niches maintain and protect AML-initiating stem cells
(
- Contribution to journal › Article
-
Mark
Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
(
- Contribution to journal › Article
-
Mark
Novel precision medicine approaches and treatment strategies in hematological malignancies
(
- Contribution to journal › Scientific review
-
Mark
An ultra-rapid screening method for acute leukemias
(
- Contribution to journal › Letter
-
Mark
Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
(
- Contribution to journal › Article
-
Mark
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
(
- Contribution to journal › Article
-
Mark
Truncated glycosyltransferase coding regions in novel ABO alleles give rise to weak A or B blood group expression and discrepant typing results
(
- Contribution to journal › Article
-
Mark
Methods for anti-factor VIII antibody levels in haemophilia A patients-validation of a multiplec immunoassay and comparability with assays measuring non-neutralising and neutralising antibodies (inhibitors)
(
- Contribution to journal › Article
-
Mark
TEMRA : the CD8 subset in chronic ITP?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Genetic Subtypes and Outcome of Patients Aged 1 to 45 Years Old with Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial
(
- Contribution to journal › Letter